This week’s biotechnology news headlines include, Ebola news, FDA advice on pivotal trials, Amgen’s leukemia drug approved, AstraZeneca and Lily begin Alzheimer drug trial, Roche acquires Ariosa Diagnostics, and Top 20 VC firms for biotech.
Cell Culture Dish – Ask the Expert Session
Our Next Session – Meet the Cells – Get your questions answered about some popular cell lines.
Do you have questions about stem cells, CHO cells, vero cells, Jurkat cells or HUVEC cells? If so, now is the time to get some answers. Whether its troubleshooting problems in your culture, understanding nutritional needs, cell vulnerabilities, or other issues, visit next week’s Ask the Expert session and submit your questions.
Session starts Monday!
Cell Culture Events
World Stem Cell Summit – December 3-5, 2014 – San Antonio, Texas
Visit Roche Custom Biotech in booth #1 to learn more about our range of solutions for Cell Therapy applications, including Liberase enzyme blends for dissociating cells from primary tissues, bio-analytical instrumentation, downstream proteases, and products for in-process quality control testing.
“U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date.”
If you like this story, please see our blog titled “Where’s the Beef!?”
“An old two-story brick building in a shabby part of town, formerly a distribution center for Budweiser beer, is now the world’s most powerful factory for analyzing genes from people and viruses.”
If you like this story, please see our blog titled “Last Week’s BioProcess International Conference and Exhibition”
“Roche said on Tuesday it will acquire San Jose, CA-based Ariosa Diagnostics, Inc., a molecular diagnostics firm which makes a prenatal test to assess the risk of Down syndrome and other genetic abnormalities.”
If you like this story, please see our blog titled “Genome Editing and Associated Technologies”
“The stampede is back on among venture capital firms to raise new money and close more funds, after years of standing pat following the recession and years of sluggish recovery.
If you like this story, please see our blog titled “Cool Tool – Creating the Perfect Scientific Poster,”